Precision medicine in oncology needs to integrate pharmacogenetic profiling

Eur Urol. 2015 Oct;68(4):630-1. doi: 10.1016/j.eururo.2015.05.039. Epub 2015 Jun 1.

Authors

Olivier Cussenot¹, Geraldine Cancel-Tassin²

Affiliations

¹ Department of Urology, Tenon Hospital, Hôpitaux Universitaires Paris-EST, Assistance publique Hôpitaux de Paris, Paris, France; CeRePP, GRC5, ONCOTYPE-URO, UPMC University Paris 06, Paris, France. Electronic address: olivier.cussenot@tnn.aphp.fr.
² CeRePP, GRC5, ONCOTYPE-URO, UPMC University Paris 06, Paris, France.

PMID: 26044803
DOI: 10.1016/j.eururo.2015.05.039

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Cytochrome P-450 CYP3A / genetics*
Female
Humans
Indoles / therapeutic use*
Kidney Neoplasms / drug therapy*
Male
Polymorphism, Single Nucleotide*
Protein Kinase Inhibitors / therapeutic use*
Pyrroles / therapeutic use*

Substances

Antineoplastic Agents
Indoles
Protein Kinase Inhibitors
Pyrroles
Cytochrome P-450 CYP3A